ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis Clinical Impact Oct 21 Written By Frances Benson https://ars-pharma.com/2022/10/21/ars-pharmaceuticals-announces-fda-acceptance-of-nda-for-neffy-epinephrine-nasal-spray-for-the-treatment-of-allergic-reactions-type-i-including-anaphylaxis/ 2022 Frances Benson
ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis Clinical Impact Oct 21 Written By Frances Benson https://ars-pharma.com/2022/10/21/ars-pharmaceuticals-announces-fda-acceptance-of-nda-for-neffy-epinephrine-nasal-spray-for-the-treatment-of-allergic-reactions-type-i-including-anaphylaxis/ 2022 Frances Benson
